NCT01650324已完成1 期
A Double-blind, Randomized, Placebo-controlled, Dose-ranging, Single-dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DBPR108 in Healthy Male Subjects
National Health Research Institutes, Taiwan1 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2012年7月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- Number of Participants With Adverse Events as a Measure of Safety and Tolerability
研究概览
简要总结
The study is being performed to assess the safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) properties of single oral doses of DBPR108 in healthy male subjects.
详细描述
This study represents the first administration of dipeptidyl peptidase 4 (DPP4) inhibitor DBPR108 to humans to evaluate the safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) properties following single oral doses in healthy subjects.
DPP4 is a validated drug target for the treatment of human type 2 diabetes. Objectives of the study will be to characterize the safety and tolerability of single doses of DBPR108; to characterize the single dose PK of DBPR108 in plasma and urine; to characterize the single dose PD of DBPR108 on glucose, glucagon, dipeptidyl peptidase 4 activity, and total and active forms of glucagon-like peptide-1 (GLP-1) in plasma levels and insulin and C-peptide in serum levels.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 20 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Male with suitable veins for cannulation or repeated venipuncture, and must be able to swallow the study drug intact;
- •Aged between 20 and 45 years (inclusive) at the screening visit; and
- •Able to provide written informed consent and willing to comply with the study protocol procedures and restrictions.
排除标准
- •Has a body weight less than 50 kg and/or body mass index (BMI) less than 18 kg/m2 or greater than 30 kg/m2 at the screening visit;
- •Has a creatinine clearance (Ccr) less than 80 mL/min at screening;
- •Is not in good general health as judged by the Investigator based on routine medical history, vital signs, physical examination, ECG, laboratory tests, and urinalysis at the screening visit or at admission for the residential period;
- •Is not normoglycemic defined as fasting glucose at less than 70 mg/dL (3.9 mmol/L) and greater than 100 mg/dL (5.5 mmol/L);
- •Has a platelet count less than 150,000/µL;
- •Uses any antihyperglycemic agents at screening or at admission for the residential period;
- •Has a history or presence of any disease or condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs at the screening visit or at admission for the residential period;
- •Has a clinically significant psychiatric, renal, hepatic, cardiovascular, gastrointestinal, or neurologic disease at screening or at admission for the residential period;
- •Is a smoker and/or has used nicotine-containing products within the last 6 months prior to the screening for the current study and/or has a history of alcohol abuse;
- •Has donated blood or participated in another clinical study within 8 weeks preceding the day of admission;
- •Excessive intake of caffeine-containing drinks or food (ie, coffee, tea, chocolate, PAOLYTA B Liq, WHISBIH Liq, or cola [more than 6 units of caffeine per day]);
- •Use of drugs with enzyme-inducing properties such as St. John's Wort within 4 weeks prior to the first administration of investigational product;
- •Has used prescription or nonprescription medication (except for occasional use of paracetamol or nasal spray) or herbal remedies or vitamins or minerals within 2 weeks or 5 half-lives of the drug, whichever is longer, prior to dosing until end of study;
- •Any intake of grapefruit, grapefruit juice, Seville oranges, Seville orange marmalade, or other products containing grapefruit or Seville oranges within 7 days of the first administration of investigational product;
- •Male subjects who are unwilling to use barrier contraception in addition to having their partner use another method of contraception, for the duration of the study and for 3 months after dosing;
- •Has a positive result on screening for serum hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCVAb), or human immunodeficiency virus (HIV);
- •Has received a blood transfusion and/or has HCV infection;
- •Positive result on screening for drugs of abuse, alcohol, or cotinine (nicotine) at screening or admission; or
- •Involved in the planning or conduct of the study.
研究组 & 干预措施
DBPR108
Experimental
干预措施: DBPR108 (Drug)
matching placebo
Placebo Comparator
干预措施: matching placebo (Drug)
结局指标
主要结局
Number of Participants With Adverse Events as a Measure of Safety and Tolerability
时间窗: Adverse events were collected from Day -1 (baseline) through the end of the study, up to Day 7.
There were 4 mild adverse events observed during the course of study.
次要结局
- Change of Dipeptidyl Peptidase 4 (DPP4) Activities Between 48 Hrs Post Dose and 0 hr Predose(predose (0 hr) and 48 hrs post dose)
- Profile of Pharmacokinetics - Area Under the Plasma Concentration-Time Curve (AUC From 0 to Infinity)(predose (0 hr), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hrs post dose)
- Profile of Pharmacokinetics - Observed Maximum Plasma Concentration (Cmax)(predose (0 hr), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hrs post dose)
- Profile of Pharmacokinetics - Time of Maximum Plasma Concentration (Tmax)(predose (0 hr), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hrs post dose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Multiple Ascending Dose Phase I Study of DBPR108 in Healthy Male SubjectsDiabetes Mellitus, Type 2NCT02163278National Health Research Institutes, Taiwan32
已完成
1 期
Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's DiseaseCentral Nervous System DiseasesAlzheimer's DiseaseNCT00766363FORUM Pharmaceuticals Inc49
招募中
1 期
A Study of HS-10501 Tablets in Healthy SubjectsHealthy SubjectsNCT06359600Jiangsu Hansoh Pharmaceutical Co., Ltd.84
已完成
1 期
An Evaluation of VR942 in Healthy Volunteers and Patients With Mild AsthmaAsthmaNCT02473939Vectura Limited85
已完成
1 期
A Study of the Safety, Tolerability, and Pharmacokinetics of SPR720 in Healthy VolunteersHealthy VolunteersNCT03796910Spero Therapeutics96